Conceptio › Archive › Google Patents

Google Patentsopen access

Delivery, engineering and optimization of systems, methods and compositions for … — The Broad Institute, Inc. (US20250250589A1)

The Broad Institute, Inc. · Google Patents

Google Patents · Patents · License: Open Access

Open Source ↗

fengzhang thebroadinstitute

patent, google patents, intellectual property, US20250250589A1, The Broad Institute, Inc., Feng Zhang, en, 2025

ABSTRACT

Abstract

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

This application is a continuation of U.S. patent application Ser. No. 15/430,260, filed Feb. 10, 2017, which is a continuation of U.S. application Ser. No. 14/183,512 filed Feb. 18, 2014, which is a continuation of U.S. application Ser. No. 14/104,837 filed Dec. 12, 2013 which claims priority to U.S. provisional patent application Nos. 61/736,527 filed Dec. 12, 2012; 61/748,427 filed Jan. 2, 2013; 61/758,468 filed Jan. 30, 2013, 61/769,046 filed Feb. 25, 2013; 61/791,409 and 61/802,174 filed Mar. 15, 2013, 61/806,375 filed Mar. 28, 2013; 61/814,263 filed Apr. 20, 2013; 61/819,803 filed May 6, 2013; 61/828,130 filed May 28, 2013; 61/835,931 and 61/836,123 filed Jun. 17, 2013 and 61/847,537 filed Jul. 17, 2013.

Reference is also made to U.S. provisional patent application Nos. 61/799,800 filed Mar. 15, 2013; 61/835,931, 61/835,936, 61/836,127, 61/836,101, 61/836,080 and 61/835,973 filed Jun. 17, 2013; 61/862,468 and 61/862,355 filed on Aug. 5, 2013; 61/871,301 filed on Aug. 28, 2013; 61/960,777 filed on Sep. 25, 2013 and 61/961,980 filed on Oct. 28, 2013.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under the NIH Pioneer Award (1DP1MH100706) awarded by the National Institutes of Health. The government has certain rights in the invention.

The foregoing applications, and all documents cited therein or during their prosecution (âappln cited documentsâ) and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein (âherein cited documentsâ), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

FIELD OF THE INVENTION

The present invention generally relates to the delivery, engineering, optimization and therapeutic applications of systems, methods, and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Apr. 16, 2025, is named 114203-6213_SL and is 453,231 bytes in size.

BACKGROUND OF THE INVENTION

Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.

SUMMARY OF THE INVENTION

The CRISPR-Cas system does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering, optimization and cell-type/tissue/organ specific delivery of these genome engineering tools, which are aspects of the claimed invention.

There exists a pressing need for alternative and robust systems and techniques for nucleic sequence targeting with a wide array of applications. Aspects of this invention address this need and provide related advantages. An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.

In one aspect, the invention provides methods for using one or more elements of a CRISPR-Cas system. The CRISPR complex of the invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utilities including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types in various tissues and organs. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene or genome editing, gene therapy, drug discovery, drug screening, disease diagnosis, and prognosis.

Aspects of the invention relate to Cas9 enzymes having improved targeting specificity in a CRISPR-Cas9 system having guide RNAs having optimal activity, smaller in length than wild-type Cas9 enzymes and nucleic acid molecules coding therefor, and chimeric Cas9 enzymes, as well as methods of improving the target specificity of a Cas9 enzyme or of designing a CRISPR-Cas9 system comprising designing or preparing guide RNAs having optimal activity and/or selecting or preparing a Cas9 enzyme having a smaller size or length than wild-type Cas9 whereby packaging a nucleic acid coding therefor into a delivery vector is more advanced as there is less coding therefor in the delivery vector than for wild-type Cas9, and/or generating chimeric Cas9 enzymes.

Also provided are uses of the present sequences, vectors, enzymes or systems, in medicine. Also provided are uses of the same in gene or genome editing.

In an additional aspect of the invention, a Cas9 enzyme may comprise one or more mutations and may be used as a generic DNA binding protein with or without fusion to a functional domain. The mutations may be artificially introduced mutations or gain- or loss-of-function mutations. The mutations may include but are not limited to mutations in one of the catalytic domains (D10 and H840) in the RuvC and HNH catalytic domains, respectively. Further mutations have been characterized. In one aspect of the invention, the transcriptional activation domain may be VP64. In other aspects of the invention, the transcriptional repressor domain may be KRAB or SID4X. Other aspects of the invention relate to the mutated Cas 9 enzyme being fused to domains which include but are not limited to a transcriptional activator, repressor, a recombinase, a transposase, a histone remodeler, a demethylase, a DNA methyltransferase, a cryptochrome, a light inducible/controllable domain or a chemically inducible/controllable domain.

In a further embodiment, the invention provides for methods to generate mutant tracrRNA and direct repeat sequences or mutant chimeric guide sequences that allow for enhancing performance of these RNAs in cells. Aspects of the invention also provide for selection of said sequences.

Aspects of the invention also provide for methods of simplifying the cloning and delivery of components of the CRISPR complex. In the preferred embodiment of the invention, a suitable promoter, such as the U6 promoter, is amplified with a DNA oligo and added onto the guide RNA. The resulting PCR product can then be transfected into cells to drive expression of the guide RNA. Aspects of the invention also relate to the guide RNA being transcribed in vitro or ordered from a synthesis company and directly transfected.

In one aspect, the invention provides for methods to improve activity by using a more active polymerase. In a preferred embodiment, the expression of guide RNAs under the control of the T7 promoter is driven by the expression of the T7 polymerase in the cell. In an advantageous embodiment, the cell is a eukaryotic cell. In a preferred embodiment the eukaryotic cell is a human cell. In a more preferred embodiment the human cell is a patient specific cell.

In one aspect, the invention provides for methods of reducing the toxicity of Cas enzymes. In certain aspects, the Cas enzyme is any Cas9 as described herein, for instance any naturally-occurring bacterial Cas9 as well as any chimaeras, mutants, homologs or orthologs. In a preferred embodiment, the Cas9 is delivered into the cell in the form of mRNA. This allows for the transient expression of the enzyme thereby reducing toxicity. In another preferred embodiment, the invention also provides for methods of expressing Cas9 under the control of an inducible promoter, and the constructs used therein.

In another aspect, the invention provides for methods of improving the in vivo applications of the CRISPR-Cas system. In the preferred embodiment, the Cas enzyme is wildtype Cas9 or any of the modified versions described herein, including any naturally-occurring bacterial Cas9 as well as any chimaeras, mutants, homologs or orthologs. An advantageous aspect of the invention provides for the selection of Cas9 homologs that are easily packaged into viral vectors for delivery. Cas9 orthologs typically share the general organization of 3-4 RuvC domains and a HNH domain. The 5â² most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand. All notations are in reference to the guide sequence.

The catalytic residue in 5â² RuvC domain is identified through homology comparison of the Cas9 of interest with other Cas9 orthologs (from S. pyogenes type II CRISPR locus, S. thermophilus CRISPR locus 1, S. thermophilus CRISPR locus 3, and Franciscilla novicida type II CRISPR locus), and the conserved Asp residue (D10) is mutated to alanine to convert Cas9 into a complementary-strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domains are mutated to Alanine to convert Cas9 into a non-complementary-strand nicking enzyme. In some embodiments, both sets of mutations may be made, to convert Cas9 into a non-cutting enzyme.

In some embodiments, the CRISPR enzyme is a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme. This type II CRISPR enzyme may be any Cas enzyme. A preferred Cas enzyme may be identified as Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system. Most preferably, the Cas9 enzyme is from, or is derived from, spCas9 or saCas9. By derived, Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein

It will be appreciated that the terms Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent. As mentioned above, many of the residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes . However, it will be appreciated that this invention includes many more Cas9s from other species of microbes, such as SpCas9, SaCas9, StlCas9 and so forth. Further examples are provided herein. The skilled person will be able to determine appropriate corresponding residues in Cas9 enzymes other than SpCas9 by comparison of the relevant amino acid sequences. Thus, where a specific amino acid replacement is referred to using the SpCas9 numbering, then, unless the context makes it apparent this is not intended to refer to other Cas9 enzymes, the disclosure is intended to encompass corresponding modifications in other Cas9 enzymes.

An example of a codon optimized sequence, in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that other examples are possible and codon optimization for a host species is known.

In further embodiments, the invention provides for methods of enhancing the function of Cas9 by generating chimeric Cas9 proteins. Chimeric Cas9 proteins chimeric Cas9s may be new Cas9 containing fragments from more than one naturally occurring Cas9. These methods may comprise fusing N-terminal fragments of one Cas9 homolog with C-terminal fragments of another Cas9 homolog. These methods also allow for the selection of new properties displayed by the chimeric Cas9 proteins.

It will be appreciated that in the present methods, where the organism is an animal or a plant, the modification may occur ex vivo or in vitro, for instance in a cell culture and in some instances not in vivo. In other embodiments, it may occur in vivo.

In one aspect, the invention provides a method of modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest comprising: delivering a non-naturally occurring or engineered composition comprising:

A)âI. a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises: (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, or (B) I. polynucleotides comprising: (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one or more tracr mate sequences, II. a polynucleotide sequence encoding a CRISPR enzyme, and III. a polynucleotide sequence comprising a tracr sequence, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex c

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under the NIH Pioneer Award (1DP1MH100706) awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

SEQUENCE LISTING

BACKGROUND OF THE INVENTION

SUMMARY OF THE INVENTION

Also provided are uses of the present sequences, vectors, enzymes or systems, in medicine. Also provided are uses of the same in gene or genome editing.

Any or all of the polynucleotide sequence encoding a CRISPR enzyme, guide sequence, tracr mate sequence or tracr sequence, may be RNA. The polynucleotides encoding the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence may be RNA and may be delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

It will be appreciated that where reference is made to a polynucleotide, which is RNA and is said to âcompriseâ a feature such a tracr mate sequence, the RNA sequence includes the feature. Where the polynucleotide is DNA and is said to comprise a feature such a tracr mate sequence, the DNA sequence is or can be transcribed into the RNA including the feature at issue. Where the feature is a protein, such as the CRISPR enzyme, the DNA or RNA sequence referred to is, or can be, translated (and in the case of DNA transcribed first).

Accordingly, in certain embodiments the invention provides a method of modifying an organism, e.g., mammal including human or a non-human mammal or organism by manipulation of a target sequence in a genomic locus of interest comprising delivering a non-naturally occurring or engineered composition comprising a viral or plasmid vector system comprising one or more viral or plasmid vectors operably encoding a composition for expression thereof, wherein the composition comprises: (A) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS), wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In some embodiments, components I, II and III are located on the same vector. In other embodiments, components I and II are located on the same vector, while component III is located on another vector. In other embodiments, components I and III are located on the same vector, while component II is located on another vector. In other embodiments, components II and III are located on the same vector, while component I is located on another vector. In other embodiments, each of components I, II and III is located on different vectors. The invention also provides a viral or plasmid vector system as described herein.

Preferably, the vector is a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-associated viral vectors, but other means of delivery are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided. In some embodiments, one or more of the viral or plasmid vectors may be delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

By manipulation of a target sequence, Applicants also mean the epigenetic manipulation of a target sequence. This may be of the chromatin state of a target sequence, such as by modification of the methylation state of the target sequence (i.e. addition or removal of methylation or methylation patterns or CpG islands), histone modification, increasing or reducing accessibility to the target sequence, or by promoting 3D folding.

It will be appreciated that where reference is made to a method of modifying an organism or mammal including human or a non-human mammal or organism by manipulation of a target sequence in a genomic locus of interest, this may apply to the organism (or mammal) as a whole or just a single cell or population of cells from that organism (if the organism is multicellular). In the case of humans, for instance, Applicants envisage, inter alia, a single cell or a population of cells and these may preferably be modified ex vivo and then re-introduced. In this case, a biopsy or other tissue or biological fluid sample may be necessary. Stem cells are also particularly preferred in this regard. But, of course, in vivo embodiments are also envisaged.

In certain embodiments the invention provides a method of treating or inhibiting a condition caused by a defect in a target sequence in a genomic locus of interest in a subject (e.g., mammal or human) or a non-human subject (e.g., mammal) in need thereof comprising modifying the subject or a non-human subject by manipulation of the target sequence and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing treatment comprising: delivering a non-naturally occurring or engineered composition comprising an AAV or lentivirus vector system comprising one or more AAV or lentivirus vectors operably encoding a composition for expression thereof, wherein the target sequence is manipulated by the composition when expressed, wherein the composition comprises: (A) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS) wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In some embodiments, components I, II and III are located on the same vector. In other embodiments, components I and II are located on the same vector, while component III is located on another vector. In other embodiments, components I and III are located on the same vector, while component II is located on another vector. In other embodiments, components II and III are located on the same vector, while component I is located on another vector. In other embodiments, each of components I, II and III is located on different vectors. The invention also provides a viral (e.g. AAV or lentivirus) vector system as described herein., and can be part of a vector system as described herein.

Some methods of the invention can include inducing expression. In some methods of the invention the organism or subject is a eukaryote (including mammal including human) or a non-human eukaryote or a non-human animal or a non-human mammal. In some embodiments, the organism or subject is a non-human animal, and may be an arthropod, for example, an insect, or may be a nematode. In some methods of the invention the organism or subject is a plant. In some methods of the invention the organism or subject is a mammal or a non-human mammal. A non-human mammal may be for example a rodent (preferably a mouse or a rat), an ungulate, or a primate. In some methods of the invention the organism or subject is algae, including microalgae, or is a fungus. In some methods of the invention the viral vector is an AAV or a lentivirus, and can be part of a vector system as described herein. In some methods of the invention the CRISPR enzyme is a Cas9. In some methods of the invention the expression of the guide sequence is under the control of the T7 promoter and is driven by the expression of T7 polymerase.

The invention in some embodiments comprehends a method of delivering a CRISPR enzyme comprising delivering to a cell mRNA encoding the CRISPR enzyme. In some of these methods the CRISPR enzyme is a Cas9.

The invention also provides methods of preparing the vector systems of the invention, in particular the viral vector systems as described herein. The invention in some embodiments comprehends a method of preparing the AAV of the invention comprising transfecting plasmid(s) containing or consisting essentially of nucleic acid molecule(s) coding for the AAV into AAV-infected cells, and supplying AAV rep and/or cap obligatory for replication and packaging of the AAV. In some embodiments the AAV rep and/or cap obligatory for replication and packaging of the AAV are supplied by transfecting the cells with helper plasmid(s) or helper virus(es). In some embodiments the helper virus is a poxvirus, adenovirus, herpesvirus or baculovirus. In some embodiments the poxvirus is a vaccinia virus. In some embodiments the cells are mammalian cells. And in some embodiments the cells are insect cells and the helper virus is baculovirus. In other embodiments, the virus is a lentivirus.

In plants, pathogens are often host-specific. For example, Fusarium oxysporum f. sp. lycopersici causes tomato wilt but attacks only tomato, and F. oxysporum f. dianthii Puccinia graminis f. sp. tritici attacks only wheat. Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants. In plants there can be non-host resistance, e.g., the host and pathogen are incompatible. There can also be Horizontal Resistance, e.g., partial resistance against all races of a pathogen, typically controlled by many genes and Vertical Resistance, e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes. In a Gene-for-Gene level, plants and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance. The sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents. Using the present invention, plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in Varieties having desired characteristics or traits employ the present invention to induce the rise of resistance genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs.

The invention further comprehends a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) for use in medicine or in therapy. In some embodiments the invention comprehends a composition according to the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) for use in a method according to the invention. In some embodiments the invention provides for the use of a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) in ex vivo gene or genome editing. In certain embodiments the invention comprehends use of a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) in the manufacture of a medicament for ex vivo gene or genome editing or for use in a method according of the invention. The invention comprehends in some embodiments a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme), wherein the target sequence is flanked at its 3â² end by a PAM (protospacer adjacent motif) sequence comprising 5â²-motif, especially where the Cas9 is (or is derived from) S. pyogenes or S. aureus Cas9. For example, a suitable PAM is 5â²-NRG or 5â²-NNGRR (where N is any Nucleotide) for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively, as mentioned below.

It will be appreciated that SpCas9 or SaCas9 are those from or derived from S. pyogenes or S. aureus Cas9.

Aspects of the invention comprehend improving the specificity of a CRISPR enzyme, e.g. Cas9, mediated gene targeting and reducing the likelihood of off-target modification by the CRISPR enzyme, e.g. Cas9. The invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a second target sequence on opposite strands of a DNA duplex in a genomic locus of interest in a cell comprising delivering a non-naturally occurring or engineered composition comprising:

I. a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence comprises: (a) a first guide sequence capable of hybridizing to the first target sequence, (b) a first tracr mate sequence, and (c) a first tracr sequence, II. a second CRISPR-Cas system chiRNA polynucleotide sequence, wherein the second polynucleotide sequence comprises: (a) a second guide sequence capable of hybridizing to the second target sequence, (b) a second tracr mate sequence, and (c) a second tracr sequence, and III. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences and comprising one or more mutations, wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein when transcribed, the first and the second tracr mate sequence hybridize to the first and second tracr sequence respectively and the first and the second guide sequence directs sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively, wherein the first CRISPR complex comprises the CRISPR enzyme complexed with (1) the first guide sequence that is hybridized to the first target sequence, and (2) the first tracr mate sequence that is hybridized to the first tracr sequence, wherein the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridized to the second target sequence, and (2) the second tracr mate sequence that is hybridized to the second tracr sequence, wherein the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, and wherein the first guide sequence directs cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directs cleavage of the other strand near the second target sequence inducing a double strand break, thereby modifying the organism or the non-human organism by minimizing off-target modifications.

In some methods of the invention any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA. In further embodiments of the invention the polynucleotides encoding the sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA and are delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun. In certain embodiments of the invention, the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity. In some embodiments, the polynucleotides may be comprised within a vector system comprising one or more vectors. In preferred embodiments of the invention the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9. In an aspect of the invention the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the CRISPR enzyme has the D10A mutation. In preferred embodiments, the first CRISPR enzyme has one or more mutations such that the enzyme is a complementary strand nicking enzyme, and the second CRISPR enzyme has one or more mutations such that the enzyme is a non-complementary strand nicking enzyme. Alternatively the first enzyme may be a non-complementary strand nicking enzyme, and the second enzyme may be a complementary strand nicking enzyme.

In preferred methods of the invention the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the other strand near the second target sequence results in a 5â² overhang. In embodiments of the invention 5â² overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention 5â² overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.

The invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a second target sequence on opposite strands of a DNA duplex in a genomic locus of interest in a cell comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to (a) a first guide sequence capable of hybridizing to the first target sequence, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to (a) a second guide sequence capable of hybridizing to the second target sequence, and (b) at least one or more tracr mate sequences, III. a third regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and IV. a fourth regulatory element operably linked to a tracr sequence, wherein components I, II, III and IV are located on the same or different vectors of the system, when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the first and the second guide sequence direct sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively, wherein the first CRISPR complex comprises the CRISPR enzyme complexed with (1) the first guide sequence that is hybridized to the first target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridized to the second target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, and wherein the first guide sequence directs cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directs cleavage of the other strand near the second target sequence inducing a double strand break, thereby modifying the organism or the non-human organism by minimizing off-target modifications.

The invention also provides a vector system as described herein. The system may comprise one, two, three or four different vectors. Components I, II, III and IV may thus be located on one, two, three or four different vectors, and all combinations for possible locations of the components are herein envisaged, for example: components I, II, III and IV can be located on the same vector; components I, II, III and IV can each be located on different vectors; components I, II, II I and IV may be located on a total of two or three different vectors, with all combinations of locations envisaged, etc.

In some methods of the invention any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA. In further embodiments of the invention the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity. In preferred embodiments of the invention the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9. In an aspect of the invention the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the CRISPR enzyme has the D10A mutation. In preferred embodiments, the first CRISPR enzyme has one or more mutations such that the enzyme is a complementary strand nicking enzyme, and the second CRISPR enzyme has one or more mutations such that the enzyme is a non-complementary strand nicking enzyme. Alternatively the first enzyme may be a non-complementary strand nicking enzyme, and the second enzyme may be a complementary strand nicking enzyme. In a further embodiment of the invention, one or more of the viral vectors are delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

In preferred methods of the invention the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of other strand near the second target sequence results in a 5â² overhang. In embodiments of the invention 5â² overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention 5â² overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.

The invention in some embodiments comprehends a method of modifying a genomic locus of interest by minimizing off-target modifications by introducing into a cell containing and expressing a double stranded DNA molecule encoding a gene product of interest an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations and two guide RNAs that target a first strand and a second strand of the DNA molecule respectively, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.

In preferred methods of the invention the Cas protein nicking each of the first strand and the second strand of the DNA molecule encoding the gene product results in a 5â² overhang. In embodiments of the invention 5â² overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention 5â² overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.

Embodiments of the invention also comprehend the guide RNAs comprising a guide sequence fused to a tracr mate sequence and a tracr sequence. In an aspect of the invention the Cas protein is codon optimized for expression in a eukaryotic cell, preferably a mammalian cell or a human cell. In further embodiments of the invention the Cas protein is a type II CRISPR-Cas protein, e.g. a Cas 9 protein. In a highly preferred embodiment the Cas protein is a Cas9 protein, e.g. SpCas9. In aspects of the invention the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the Cas protein has the D10A mutation.

The invention also comprehends an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations and two guide RNAs that target a first strand and a second strand respectively of a double stranded DNA molecule encoding a gene product in a cell, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.

In aspects of the invention the guide RNAs may comprise a guide sequence fused to a tracr mate sequence and a tracr sequence. In an embodiment of the invention the Cas protein is a type II CRISPR-Cas protein. In an aspect of the invention the Cas protein is codon optimized for expression in a eukaryotic cell, preferably a mammalian cell or a human cell. In further embodiments of the invention the Cas protein is a type II CRISPR-Cas protein, e.g. a Cas 9 protein. In a highly preferred embodiment the Cas protein is a Cas9 protein, e.g. SpCas9. In aspects of the invention the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the Cas protein has the D10A mutation.

The invention also comprehends an engineered, non-naturally occurring vector system comprising one or more vectors comprising:

a) a first regulatory element operably linked to each of two CRISPR-Cas system guide RNAs that target a first strand and a second strand respectively of a double stranded DNA molecule encoding a gene product, b) a second regulatory element operably linked to a Cas protein, wherein components (a) and (b) are located on same or different vectors of the system, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.

Aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5â² overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased. In an embodiment of the invention, the gene product is a protein. In preferred embodiments of the invention the vectors of the system are viral vectors. In a further embodiment, the vectors of the system are delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments, said vectors are delivered to the eukaryotic cell in a subject. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from a subject prior to said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject.

In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.

In one aspect, the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, a disease gene is any gene associated with an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.

In one aspect the invention provides for a method of selecting one or more prokaryotic cell(s) by introducing one or more mutations in a gene in the one or more prokaryotic cell(s), the method comprising: introducing one or more vectors into the prokaryotic cell(s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a t

CLAIMS

Claims ( 21 )

1 . (canceled)

2 . A method for editing a mammalian subject in vivo, comprising delivering an engineered CRISPR-Cas system into the mammalian subject, wherein the engineered CRISPR-Cas system comprises:

(a) a Cas9 protein or a polynucleotide encoding the Cas9 protein, wherein the Cas9 protein is S. pyogenes Cas9 and is fused with two or more nuclear localization signals (NLSs); (b) a CRISPR-Cas system chimeric RNA or a polynucleotide encoding the chimeric RNA, wherein the chimeric RNA comprises a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a genomic locus of interests of a mammalian cell, a tracr-mate sequence capable of hybridizing to a tracr sequence, and a tracr sequence comprising 40 or more nucleotides in length; wherein a CRISPR complex comprising the Cas9 protein and the chimeric RNA is formed in the mammalian cell in vivo, and wherein the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence adjacent to the PAM in the genomic locus of interests of the mammalian cell.

3 . The method of claim 2 , wherein the PAM is NGG.

4 . The method of claim 2 , wherein the tracr sequence comprises 50 or more nucleotides in length.

5 . The method of claim 2 , wherein the chimeric RNA comprises

NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAU

AAGGCUAGUCCGUUAUCA.

6 . The method of claim 2 , wherein the chimeric RNA further comprises a poly-U sequence.

7 . The method of claim 2 , wherein the chimeric RNA is encoded by SEQ ID NO:86.

8 . The method of claim 2 , wherein the chimeric RNA comprises one or more modified nucleotides.

9 . The method of claim 2 , wherein the chimeric RNA comprises one or more methylated nucleotides or nucleotide analogs.

10 . The method of claim 2 , wherein the two or more NLSs are independently selected from the group consisting of PKKKRKV, KRPAATKKAGQAKKKK, PAAKRVKLD, RQRRNELKRSP, NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY, RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV, VSRKRPRP, PPKKARED, PQPKKKPL, SALIKKKKKMAP, DRLRR, PKQKKRK, RKLKKKIKKL, REKKKFLKRR, KRKGDEVDGVDEVAKKKSKK, and RKCLQAGMNLEARKTKK.

11 . The method of claim 10 , wherein at least one of the NLSs comprises PKKKRKV.

12 . The method of claim 2 , wherein the Cas9 protein comprises a mutation of D10A, H840A, N854A, or N863A.

13 . The method of claim 12 , wherein the Cas9 protein is fused with at least one heterologous protein domain.

14 . The method of claim 13 , wherein the heterologous protein domain is selected from the group consisting of epitope tags, reporter sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, or nucleic acid binding activity.

15 . The method of claim 2 , wherein the polynucleotide encoding the Cas9 protein is codon-optimized for expression in the mammalian cell.

16 . The method of claim 2 , wherein the polynucleotide encoding the Cas9 protein comprises a polyadenylation signal.

17 . The method of claim 2 , wherein the CRISPR-Cas system is comprised in a liposome for delivery.

18 . The method of claim 2 , further comprising delivering into the mammalian cell an exogenous polynucleotide for targeted integration into a DNA break introduced by the CRISPR complex.

19 . The method of claim 2 , wherein the CRISPR complex cleaves the genomic locus of interest, and wherein the mammalian cell is modified in vivo with an insertion, deletion, or substitution of one or more nucleotides in the genomic locus of interest.

20 . A method for editing a human subject in vivo, comprising delivering an engineered CRISPR-Cas system into the human subject, wherein the engineered CRISPR-Cas system comprises:

(a) a Cas9 protein or a polynucleotide encoding the Cas9 protein, wherein the Cas9 protein is S. pyogenes Cas9 and is fused with two or more nuclear localization signals (NLSs) independently selected from the group consisting of PKKKRKV, KRPAATKKAGQAKKKK, PAAKRVKLD, RQRRNELKRSP, NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY, RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV, VSRKRPRP, PPKKARED, PQPKKKPL, SALIKKKKKMAP, DRLRR, PKQKKRK, RKLKKKIKKL, REKKKFLKRR, KRKGDEVDGVDEVAKKKSKK, and RKCLQAGMNLEARKTKK; (b) a CRISPR-Cas system chimeric RNA or a polynucleotide encoding the chimeric RNA, wherein the chimeric RNA comprises NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG CUAGUCCGUUAUCA, wherein NNNNNNNNNNNNNNNNNNNN is a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a genomic locus of interests of a human cell; wherein a CRISPR complex comprising the Cas9 protein and the chimeric RNA is formed in the human cell in vivo, and wherein the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence adjacent to the PAM in the genomic locus of interests of the human cell.

21 . A method for editing a human subject in vivo, comprising delivering an engineered CRISPR-Cas system into the human subject, wherein the engineered CRISPR-Cas system comprises:

(a) a polynucleotide encoding a Cas9 protein, wherein the Cas9 protein is S. pyogenes Cas9 and is fused with two or more nuclear localization signals (NLSs) independently selected from the group consisting of PKKKRKV, KRPAATKKAGQAKKKK, PAAKRVKLD, RQRRNELKRSP, NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY, RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV, VSRKRPRP, PPKKARED, PQPKKKPL, SALIKKKKKMAP, DRLRR, PKQKKRK, RKLKKKIKKL, REKKKFLKRR, KRKGDEVDGVDEVAKKKSKK, and RKCLQAGMNLEARKTKK, wherein the polynucleotide is codon-optimized for expression in the mammalian cell and comprises a polyadenylation signal; (b) a CRISPR-Cas system chimeric RNA comprising NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG CUAGUCCGUUAUCA, wherein NNNNNNNNNNNNNNNNNNNN is a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a genomic locus of interests of a human cell; wherein a CRISPR complex comprising the Cas9 protein and the chimeric RNA is formed in the human cell in vivo, wherein the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence adjacent to the PAM in the genomic locus of interests, wherein the CRISPR complex cleaves the genomic locus of interest in the human cell.

US19/025,611

2012-12-12

2025-01-16

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Pending

US20250250589A1

( en )

Priority Applications (1)

Application Number

Priority Date

Filing Date

Title

US19/025,611

US20250250589A1

( en )

2012-12-12

2025-01-16

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Applications Claiming Priority (17)

Application Number

Priority Date

Filing Date

Title

US201261736527P

2012-12-12

US201361748427P

2013-01-02

US201361758468P

2013-01-30

US201361769046P

2013-02-25

US201361802174P

2013-03-15

US201361791409P

2013-03-15

US201361806375P

2013-03-28

US201361814263P

2013-04-20

US201361819803P

2013-05-06

US201361828130P

2013-05-28

US201361836123P

2013-06-17

US201361835931P

2013-06-17

US201361847537P

2013-07-17

US14/104,837

US20140179770A1

( en )

2012-12-12

2013-12-12

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US14/183,512

US20140242699A1

( en )

2012-12-12

2014-02-18

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US15/430,260

US20170152528A1

( en )

2012-12-12

2017-02-10

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US19/025,611

US20250250589A1

( en )

2012-12-12

2025-01-16

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Related Parent Applications (1)

Application Number

Title

Priority Date

Filing Date

US15/430,260

Continuation

US20170152528A1

( en )

2012-12-12

2017-02-10

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Publications (1)

Publication Number

Publication Date

US20250250589A1

true

US20250250589A1 ( en )

2025-08-07

Family

ID=49883289

Family Applications (10)

Application Number

Title

Priority Date

Filing Date

US14/104,837

Abandoned

US20140179770A1

( en )

2012-12-12

2013-12-12

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US14/183,512

Abandoned

US20140242699A1

( en )

2012-12-12

2014-02-18

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US14/481,339

Abandoned

US20150020223A1

( en )

2012-12-12

2014-09-09

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US15/349,603

Active

US11041173B2

( en )

2012-12-12

2016-11-11

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US15/430,260

Pending

US20170152528A1

( en )

2012-12-12

2017-02-10

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US17/245,952

Active

2036-03-11

US12252707B2

( en )

2012-12-12

2021-04-30

Delivery, Engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US18/217,352

Pending

US20240035048A1

( en )

2012-12-12

2023-06-30

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US18/217,357

Pending

US20230399662A1

( en )

2012-12-12

2023-06-30

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US19/025,611

Pending

US20250250589A1

( en )

2012-12-12

2025-01-16

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US19/079,830

Pending

US20250382642A1

( en )

2012-12-12

2025-03-14

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Family Applications Before (8)

Application Number

Title

Priority Date

Filing Date

US14/104,837

Abandoned

US20140179770A1

( en )

2012-12-12

2013-12-12

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US14/183,512

Abandoned

US20140242699A1

( en )

2012-12-12

2014-02-18

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US14/481,339

Abandoned

US20150020223A1

( en )

2012-12-12

2014-09-09

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US15/349,603

Active

US11041173B2

( en )

2012-12-12

2016-11-11

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US15/430,260

Pending

US20170152528A1

( en )

2012-12-12

2017-02-10

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US17/245,952

Active

2036-03-11

US12252707B2

( en )

2012-12-12

2021-04-30

Delivery, Engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US18/217,352

Pending

US20240035048A1

( en )

2012-12-12

2023-06-30

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

US18/217,357

Pending

US20230399662A1

( en )

2012-12-12

2023-06-30

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Family Applications After (1)

Application Number

Title

Priority Date

Filing Date

US19/079,830

Pending

US20250382642A1

( en )

2012-12-12

2025-03-14

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

Country Status (15)

Country

Link

( 10 )

US20140179770A1

( en )

( 5 )

EP4299741A3

( en )

( 5 )

JP2016501531A

( en )

( 1 )

KR20150105956A

( en )

( 2 )

CN110872583A

( en )

( 4 )

AU2013359199C1

( en )

( 1 )

BR112015013784A2

( en )

( 2 )

DK2931897T3

( en )

( 2 )

ES2883590T3

( en )

( 2 )

IL239317B

( en )

( 2 )

MX389793B

( en )

( 1 )

RU2721275C2

( en )

( 3 )

SG10201707569YA

( en )

( 1 )

WO2014093622A2

( en )

( 1 )

ZA201504132B

( en )

Families Citing this family (918)

* Cited by examiner, â Cited by third party

Publication number

Priority date

Publication date

Assignee

Title

US9217155B2

( en )

2008-05-28

2015-12-22

University Of Massachusetts

Isolation of novel AAV'S and uses thereof

WO2010138263A2

( en )

2009-05-28

2010-12-02

University Of Massachusetts

Novel aav 's and uses thereof

CN102638971B

( en )

2009-07-08

2015-10-07

ç§é©¬å¸æéå¬å¸

Animal Models and Therapeutic Molecules

US9445581B2

( en )

2012-03-28

2016-09-20

Kymab Limited

Animal models and therapeutic molecules

US9272053B2

( en )

2010-04-23

2016-03-01

University Of Massachusetts

AAV-based treatment of cholesterol-related disorders

WO2011140441A2

( en )

2010-05-06

2011-11-10

Children's Hospital Medical Center

Methods and systems for converting precursor cells into intestinal tissues through directed differentiation

CN109593814A

( en )

2010-05-12

2019-04-09

å¥ä¼¦æ¯äºå¤§å¦çº½çº¦ç®¡çå§åä¼

Screening analysis, the method and pharmaceutical composition for identifying medicament

EP2689019A2

( en )

2011-03-23

2014-01-29

Pioneer Hi-Bred International Inc.

Methods for producing a complex transgenic trait locus

JP2014511687A

( en )

2011-03-31

2014-05-19

ã¢ãã«ã ã»ã©ãã¥ã¼ãã£ã¯ã¹ ã¤ã³ã³ã¼ãã¬ã¤ããã

Engineered nucleic acid delivery and formulation

US9226976B2

( en )

2011-04-21

2016-01-05

University Of Massachusetts

RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies

WO2013066438A2

( en )

2011-07-22

2013-05-10

President And Fellows Of Harvard College

Evaluation and improvement of nuclease cleavage specificity

AU2012311286B2

( en )

2011-09-19

2018-07-26

Kymab Limited

Antibodies, variable domains and chains tailored for human use

WO2013045916A1

( en )

2011-09-26

2013-04-04

Kymab Limited

Chimaeric surrogate light chains (slc) comprising human vpreb

GB201117313D0

( en )

2011-10-07

2011-11-16

Gt Biolog Ltd

Bacterium for use in medicine

EP3604555B1

( en )

2011-10-14

2024-12-25

President and Fellows of Harvard College

Sequencing by structure assembly

US9253965B2

( en )

2012-03-28

2016-02-09

Kymab Limited

Animal models and therapeutic molecules

ES2991004T3

( en )

2011-12-22

2024-12-02

Harvard College

Methods for the detection of analytes

WO2014163886A1

( en )

2013-03-12

2014-10-09

President And Fellows Of Harvard College

Method of generating a three-dimensional nucleic acid containing matrix

GB201122458D0

( en )

2011-12-30

2012-02-08

Univ Wageningen

Modified cascade ribonucleoproteins and uses thereof

US9745548B2

( en )

2012-03-15

2017-08-29

Flodesign Sonics, Inc.

Acoustic perfusion devices

US10322949B2

( en )

2012-03-15

2019-06-18

Flodesign Sonics, Inc.

Transducer and reflector configurations for an acoustophoretic device

US10689609B2

( en )

2012-03-15

2020-06-23

Flodesign Sonics, Inc.

Acoustic bioreactor processes

US9458450B2

( en )

2012-03-15

2016-10-04

Flodesign Sonics, Inc.

Acoustophoretic separation technology using multi-dimensional standing waves

US9752113B2

( en )

2012-03-15

2017-09-05

Flodesign Sonics, Inc.

Acoustic perfusion devices

US9950282B2

( en )

2012-03-15

2018-04-24

Flodesign Sonics, Inc.

Electronic configuration and control for acoustic standing wave generation

US10967298B2

( en )

2012-03-15

2021-04-06

Flodesign Sonics, Inc.

Driver and control for variable impedence load

US10704021B2

( en )

2012-03-15

2020-07-07

Flodesign Sonics, Inc.

Acoustic perfusion devices

US9637739B2

( en )

2012-03-20

2017-05-02

Vilnius University

RNA-directed DNA cleavage by the Cas9-crRNA complex

US10039777B2

( en )

2012-03-20

2018-08-07

Neuro-Lm Sas

Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders

US10251377B2

( en )

2012-03-28

2019-04-09

Kymab Limited

Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies

GB2502127A

( en )

2012-05-17

2013-11-20

Kymab Ltd

Multivalent antibodies and in vivo methods for their production

US10737953B2

( en )

2012-04-20

2020-08-11

Flodesign Sonics, Inc.

Acoustophoretic method for use in bioreactors

RU2645475C2

( en )

2012-04-25

2018-02-21

Ð ÐµÐ³ÐµÐ½ÐµÑÐ¾Ð½ Ð¤Ð°ÑÐ¼Ð°ÑÑÑÑÐ¸ÐºÐ°Ð»Ð·, ÐÐ½Ðº.

Nuclease-mediated targeting with large targeting vectors

WO2013163628A2

( en )

2012-04-27

2013-10-31

Duke University

Genetic correction of mutated genes

EP2847215A1

( en )

2012-05-07

2015-03-18

Synthes GmbH

Methods and devices for treating intervertebral disc disease

LT3401400T

( en )

2012-05-25

2019-06-10

The Regents Of The University Of California

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

CA2875618C

( en )

2012-07-11

2021-04-27

Sangamo Biosciences, Inc.

Methods and compositions for the treatment of lysosomal storage diseases

US10648001B2

( en )

2012-07-11

2020-05-12

Sangamo Therapeutics, Inc.

Method of treating mucopolysaccharidosis type I or II

PL4397760T3

( en )

2012-10-23

2026-03-30

Toolgen Incorporated

A COMPOSITION FOR CLEFULNING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR A TARGET DNA AND A NUCLEIC ACID ENCODING A CAS PROTEIN OR A CAS PROTEIN, AND USE THEREOF

EP3135765A1

( en )

2012-12-06

2017-03-01

Sigma-Aldrich Co. LLC

Crispr-based genome modification and regulation

CN114634950A

( en )

2012-12-12

2022-06-17

CRISPR-CAS component systems, methods, and compositions for sequence manipulation

EP2931898B1

( en )

2012-12-12

2016-03-09

The Broad Institute, Inc.

Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains

IL239317B

( en )

2012-12-12

2022-07-01

Broad Inst Inc

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

ES2576126T3

( en )

2012-12-12

2016-07-05

The Broad Institute, Inc.

Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation

EP3434776A1

( en )

2012-12-12

2019-01-30

The Broad Institute, Inc.

Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof

EP2896697B1

( en )

2012-12-12

2015-09-02

The Broad Institute, Inc.

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US8697359B1

( en )

2012-12-12

2014-04-15

The Broad Institute, Inc.

CRISPR-Cas systems and methods for altering expression of gene products

WO2014093701A1

( en )

2012-12-12

2014-06-19

The Broad Institute, Inc.

Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof

SG10201912991WA

( en )

2012-12-17

2020-03-30

Harvard College

Rna-guided human genome engineering

EP3919505B1

( en )

2013-01-16

2023-08-30

Emory University

Uses of cas9-nucleic acid complexes

SG11201507378UA

( en )

2013-03-14

2015-10-29

Caribou Biosciences Inc

Compositions and methods of nucleic acid-targeting nucleic acids

US10378027B2

( en )

2013-03-15

2019-08-13

The General Hospital Corporation

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

US9234213B2

( en )

2013-03-15

2016-01-12

System Biosciences, Llc

Compositions and methods directed to CRISPR/Cas genomic engineering systems

US10760064B2

( en )

2013-03-15

2020-09-01

The General Hospital Corporation

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

US10077439B2

( en )

2013-03-15

2018-09-18

Modernatx, Inc.

Removal of DNA fragments in mRNA production process

US11332719B2

( en )

2013-03-15

2022-05-17

The Broad Institute, Inc.

Recombinant virus and preparations thereof

WO2014204578A1

( en )

2013-06-21

2014-12-24

The General Hospital Corporation

Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing

EP2971161B1

( en )

2013-03-15

2018-12-26

ModernaTX, Inc.

Ribonucleic acid purification

US9788534B2

( en )

2013-03-18

2017-10-17

Kymab Limited

Animal models and therapeutic molecules

US9828582B2

( en )

2013-03-19

2017-11-28

Duke University

Compositions and methods for the induction and tuning of gene expression

JP6576904B2

( en )

2013-04-04

2019-09-18

Compositions and methods for in vivo excision of HIV-1 proviral DNA

JP2016522679A

( en )

2013-04-04

2016-08-04

ãã¬ã¸ãã³ã ã¢ã³ã ãã§ãã¼ãº ãªã ãã¼ãã¼ã ã«ã¬ãã¸

Therapeutic use of genome editing with the CRISPR / Cas system

GB201306536D0

( en )

2013-04-10

2013-05-22

Gt Biolog Ltd

Polypeptide and immune modulation

DK2986729T3

( en )

2013-04-16

2018-10-29

Regeneron Pharma

TARGETED MODIFICATION OF ROOT THROUGH

US9783618B2

( en )

2013-05-01

2017-10-10

Kymab Limited

Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics

US9783593B2

( en )

2013-05-02

2017-10-10

Kymab Limited

Antibodies, variable domains and chains tailored for human use

US11707056B2

( en )

2013-05-02

2023-07-25

Kymab Limited

Animals, repertoires and methods

EP3730615A3

( en )

2013-05-15

2020-12-09

Sangamo Therapeutics, Inc.

Methods and compositions for treatment of a genetic condition

ES2670531T3

( en )

2013-05-29

2018-05-30

Cellectis S.A.

A method to produce an accurate DNA cleavage using the nickase activity of Cas9

US20140356956A1

( en )

2013-06-04

2014-12-04

President And Fellows Of Harvard College

RNA-Guided Transcriptional Regulation

SG10201710030QA

( en )

2013-06-04

2018-01-30

Harvard College

Rna-guided transcriptional regulation

CN105793425B

( en )

2013-06-17

2021-10-26

Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components

MX2015017312A

( en )

2013-06-17

2017-04-10

Broad Inst Inc

SUPPLY AND USE OF CRISPR-CAS COMPOSITIONS, VECTORS AND SYSTEMS FOR DIRECTED MODIFICATION AND HEPATIC THERAPY.

JP6665088B2

( en )

2013-06-17

2020-03-13

ã¶ã»ããã¼ãã»ã¤ã³ã¹ãã£ãã¥ã¼ãã»ã¤ã³ã³ã¼ãã¬ã¤ããã

Optimized CRISPR-Cas double nickase system, method and composition for sequence manipulation

EP3725885A1

( en )

2013-06-17

2020-10-21

The Broad Institute, Inc.

Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof

WO2014204724A1

( en )

2013-06-17

2014-12-24

The Broad Institute Inc.

Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation

JP2016528890A

( en )

2013-07-09

2016-09-23

ãã¬ã¸ãã³ã ã¢ã³ã ãã§ãã¼ãº ãªã ãã¼ãã¼ã ã«ã¬ãã¸

Therapeutic use of genome editing using the CRISPR / Cas system

BR112016000571B1

( en )

2013-07-10

2023-12-26

President And Fellows Of Harvard College

IN VITRO METHODS FOR MODULATING EXPRESSION AND FOR ALTERING ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL SIMULTANEOUSLY WITH REGULATING THE EXPRESSION OF ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL AS WELL AS A YEAST OR BACTERIAL CELL COMPRISING NUCLEIC ACIDS

HUE056760T2

( en )

2013-07-11

2022-03-28

Modernatx Inc

Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use

JP6482546B2

( en )

2013-07-19

2019-03-13

Methods and compositions for generating double allelic knockouts

US10563225B2

( en )

2013-07-26

2020-02-18

President And Fellows Of Harvard College

Genome engineering

US20150044192A1

( en )

2013-08-09

2015-02-12

President And Fellows Of Harvard College

Methods for identifying a target site of a cas9 nuclease

US9359599B2

( en )

2013-08-22

2016-06-07

President And Fellows Of Harvard College

Engineered transcription activator-like effector (TALE) domains and uses thereof

CA3221516A1

( en )

2013-08-22

2015-02-26

E. I. Du Pont De Nemours And Company

Plant genome modification using guide rna/cas endonuclease systems and methods of use

CA2922428A1

( en )

2013-08-29

2015-03-05

Temple University Of The Commonwealth System Of Higher Education

Methods and compositions for rna-guided treatment of hiv infection

US9526784B2

( en )

2013-09-06

2016-12-27

President And Fellows Of Harvard College

Delivery system for functional nucleases

Delivery, engineering and optimization of systems, methods and compositions for … — The Broad Institute, Inc. (US20250250589A1)

Related documents